A detailed history of Geode Capital Management, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,559,772 shares of VERV stock, worth $8.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,559,772
Previous 1,449,426 7.61%
Holding current value
$8.63 Million
Previous $19.2 Million 60.46%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$4.76 - $12.79 $525,246 - $1.41 Million
110,346 Added 7.61%
1,559,772 $7.61 Million
Q1 2024

May 13, 2024

BUY
$10.81 - $17.96 $3.45 Million - $5.73 Million
319,263 Added 28.25%
1,449,426 $19.2 Million
Q4 2023

Feb 13, 2024

BUY
$8.84 - $18.7 $683,181 - $1.45 Million
77,283 Added 7.34%
1,130,163 $15.8 Million
Q3 2023

Nov 13, 2023

BUY
$11.42 - $20.82 $1.1 Million - $2 Million
96,153 Added 10.05%
1,052,880 $14 Million
Q2 2023

Aug 11, 2023

BUY
$13.34 - $19.9 $946,553 - $1.41 Million
70,956 Added 8.01%
956,727 $17.9 Million
Q1 2023

May 15, 2023

BUY
$14.3 - $24.01 $543,943 - $913,292
38,038 Added 4.49%
885,771 $12.8 Million
Q4 2022

Feb 13, 2023

BUY
$17.85 - $40.7 $1.16 Million - $2.65 Million
65,021 Added 8.31%
847,733 $16.4 Million
Q3 2022

Nov 14, 2022

BUY
$15.63 - $41.49 $4.93 Million - $13.1 Million
315,492 Added 67.53%
782,712 $26.9 Million
Q2 2022

Aug 12, 2022

BUY
$11.14 - $23.17 $456,205 - $948,857
40,952 Added 9.61%
467,220 $7.14 Million
Q1 2022

May 13, 2022

BUY
$20.92 - $39.36 $2.84 Million - $5.35 Million
135,800 Added 46.75%
426,268 $9.73 Million
Q4 2021

Feb 11, 2022

BUY
$31.94 - $54.82 $500,308 - $858,700
15,664 Added 5.7%
290,468 $10.7 Million
Q3 2021

Nov 12, 2021

BUY
$46.0 - $73.99 $11.2 Million - $18 Million
242,702 Added 756.03%
274,804 $12.9 Million
Q2 2021

Aug 13, 2021

BUY
$31.92 - $60.25 $1.02 Million - $1.93 Million
32,102 New
32,102 $1.93 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $331M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.